| Shelly Marie Whaley, CRNP | |
|
3316 Us - 280 E, Alexander City, AL 35010 | |
| (256) 329-7100 | |
| Not Available |
| Full Name | Shelly Marie Whaley |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 3316 Us - 280 E, Alexander City, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093351256 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 1-093346 (Alabama) | Secondary |
| 363L00000X | Nurse Practitioner | 1-093346 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Russell Medical Center | Alexander city, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Russell Hospital Corporation | 6406754431 | 52 |
| Advanced Cardiovascular, Llc | 9234309139 | 4 |
News Archive
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.
Patients who were sexually active before suffering a heart attack were one and a half times more likely to recapture their sex lives if they received guidance on the topic before leaving the hospital, a new study finds.
› Verified 5 days ago
| Entity Name | The Russell Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811913460 PECOS PAC ID: 6406754431 Enrollment ID: O20040109000579 |
News Archive
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.
Patients who were sexually active before suffering a heart attack were one and a half times more likely to recapture their sex lives if they received guidance on the topic before leaving the hospital, a new study finds.
› Verified 5 days ago
| Entity Name | The Russell Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417252537 PECOS PAC ID: 6406754431 Enrollment ID: O20110307000502 |
News Archive
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.
Patients who were sexually active before suffering a heart attack were one and a half times more likely to recapture their sex lives if they received guidance on the topic before leaving the hospital, a new study finds.
› Verified 5 days ago
| Entity Name | Advanced Cardiovascular, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659669307 PECOS PAC ID: 9234309139 Enrollment ID: O20110901000465 |
News Archive
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.
Patients who were sexually active before suffering a heart attack were one and a half times more likely to recapture their sex lives if they received guidance on the topic before leaving the hospital, a new study finds.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shelly Marie Whaley, CRNP 9758 Coosa County Road 40, Rockford, AL 35136-4106 Ph: (256) 794-0222 | Shelly Marie Whaley, CRNP 3316 Us - 280 E, Alexander City, AL 35010 Ph: (256) 329-7100 |
News Archive
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
Bose Corporation has introduced DuraPulse™, a new instrument for accelerated durability testing of heart valve replacement devices. Featuring proprietary Bose® controls and linear motor technology, the DuraPulse system enables research and development engineers to run tests at frequencies higher than ever before - exceeding 30 Hz without the loss of waveform fidelity. And with Bose PeakIQ™ control technology, the DuraPulse system also prevents high-pressure spikes during valve closing.
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.
Patients who were sexually active before suffering a heart attack were one and a half times more likely to recapture their sex lives if they received guidance on the topic before leaving the hospital, a new study finds.
› Verified 5 days ago
Sheena C Hunter, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 44 Aliant Pkwy, Alexander City, AL 35010 Phone: 256-234-4131 Fax: 256-234-9979 | |
Mrs. Chloe L. Elrod, MSN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3368 Highway 280 Ste 130, Alexander City, AL 35010 Phone: 256-234-2644 | |
Maria Luisa Coxey, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3316 Highway 280, Alexander City, AL 35010 Phone: 256-329-7100 | |
Mrs. Kayla Kizziah Tidwell, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3316 Highway 280, Alexander City, AL 35010 Phone: 256-329-7100 | |
Amanda Hardy, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1120 Airport Dr, Alexander City, AL 35010 Phone: 256-212-9300 | |
Emily Shelby, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2508 Highway 280, Alexander City, AL 35010 Phone: 256-414-3013 | |
Jason Paul Jones, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3316 Highway 280, Alexander City, AL 35010 Phone: 256-329-7100 |